Tamoxifen was associated with lower all-cause mortality in early-stage breast cancer, whereas aromatase inhibitors were linked to higher all-cause mortality and increased COVID-19-related hospitalization in locally advanced disease. The gene discussed is CYP19A1; the disease is COVID-19.